Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07785388 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Genistein for the Reduction of Adverse Cardiovascular Events (GRACE)

Study acronym: GRACE
StatusNot Yet Recruiting
PhasePhase 1/2
Started2026-09-30
View on ClinicalTrials.gov ↗
People living with HIV (PLHIV) live longer because of modern HIV medicines, but even with these treatments, their bodies are more inflamed. Long term inflammation increases the risk of heart disease, chronic pain, lung disease, dementia, arthritis, and other infections. Because some anti-inflammatory medicines can cause serious side effects, interact with HIV drugs, or be costly, safer and more affordable treatment options are needed. Genistein is a natural compound found in soy foods. It is considered safe and has been shown to reduce inflammation and improve blood vessel health. This study will test whether genistein can lower inflammation in the blood, improve blood vessel health, and reduce pain in PLHIV.
Trial Details
NCT Number NCT07785388
Lead Sponsor London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborators: Greenstone Biosciences, Inc.
Conditions HIV, Vascular Disease, Inflammation, Pain Management
Enrollment 60 participants
Start Date 2026-09-30
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-25